Bibliography
- Enquist E , ZambianoN, ZbarB et al.: Molecular mechanisms of immune dysfunction in renal cell carcinoma. In: Renal Cell Carcinoma. Molecular Biology, Immunology and Clinical Management. Bukowski RM, Novick AC (Eds). Humana Press, Totowa, NJ, USA 63–78 (2000).
- Coppin C , PorzsoltF, AwaA, KumpfJ, ColdmanA, WiltT: Immunotherapy for advanced renal cell cancer.Cochrane Database Syst. Rev. (1) , CD001425 (2005).
- Demirer T , BarkholtL, BlaiseD et al.: Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors.Nat. Clin. Pract. Oncol.5 , 256–267 (2008).
- Rosenberg SA , YangJC, WhiteDE, SteinbergSM: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.Ann. Surg.228 , 307–319 (1998).
- McDermott DF , GhebremichaelMS, SignorettiS et al.: The high-dose aldesleukin (HD IL-2) ‘SELECT‘ trial in patients with metastatic renal cell carcinoma (mRCC).J. Clin. Oncol.28(Suppl. 15) , Abstract 4514 (2010).
- Grepin R , PagèsG: Molecular mechanisms of resistance to tumor anti-angiogenic strategies.J. Oncol. DOI:10.1155/2010/835680 (2010).
- Loges S , SchmidtT, CarmelietP: Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates.Genes Cancer1 , 12–25 (2010).
- Shojaei F , WuX, MalikAK et al.: Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.Nat. Biotechnol.25 , 911–920 (2007).
- Marigo L , DolcettiL, SerafiniP, ZanovelloP, BronteV: Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.Immunol. Rev.222 , 162–179 (2008).
- Heinrich PC , BehrmannI, HaanS, HermannsHM, Muller-NewenG, SchaperF: Principles of interleukin (IL)-6-type cytokine signalling and its regulation.Biochem. J.374 , 1–20 (2003).
- Kallen KJ : The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases.Biochim. Biophys. Acta1592 , 323–343 (2002).
- Blay JY , NegrierS, CombaretV et al.: Serum level of Interleukin-6 as a prognostic factor in metastatic renal cell carcinoma.Cancer Res.52 , 3317–3322 (1992).
- Negrier S , PerolD, Menetrier-CauxC et al.: Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 from the Groupe Francais d‘Immunotherapie.J. Clin. Oncol.22 , 2371–2378 (2004).
- Fumagalli L , LissoniP, Di Felice G et al.: Pre-treatment serum markers and lymphocyte response to interleukin-2 therapy. Br. J. Cancer80 , 407–411 (1999).
- Capuron L , RavaudA, GualdeN et al.: Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy.Psychoneuroendocrinolgy26 , 797–808 (2001).
- Rossi JF , NegrierS, JamesND et al.: A Phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer.Br. J. Cancer103 , 1154–1162 (2010).
- Van Zaanen HC , KoopmansRP, AardenLA et al.: Endogenous interleukin-6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL-6 antibodies indicates the existence of a positive feed-back loop.J. Clin. Invest.98 , 1441–1448 (1996).
- Correale P , CusiMG, TaglaferriP: Immunomodulatory properties of anticancer monoclonal antibodies: is the ‘magic bullet‘ still a reliable paradigm?Immunotherapy3 , 1–4 (2011).